Equities Analysts Set Expectations for VRTX Q3 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Investment analysts at Zacks Research reduced their Q3 2026 earnings estimates for Vertex Pharmaceuticals in a research report issued to clients and investors on Monday, March 3rd. Zacks Research analyst R. Department now expects that the pharmaceutical company will earn $4.13 per share for the quarter, down from their prior estimate of $4.15. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ FY2027 earnings at $17.79 EPS.

Several other equities research analysts have also weighed in on VRTX. Canaccord Genuity Group raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and increased their target price for the stock from $408.00 to $424.00 in a research report on Tuesday, February 11th. Piper Sandler reduced their target price on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. BMO Capital Markets set a $545.00 price objective on Vertex Pharmaceuticals in a research report on Friday, January 31st. Finally, William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $506.70.

Vertex Pharmaceuticals Stock Up 1.1 %

Shares of Vertex Pharmaceuticals stock opened at $491.64 on Wednesday. Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88. The stock has a market capitalization of $126.25 billion, a price-to-earnings ratio of -223.47, a PEG ratio of 2.11 and a beta of 0.41. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The business’s 50 day simple moving average is $445.18 and its 200-day simple moving average is $461.33.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%.

Institutional Trading of Vertex Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Truvestments Capital LLC increased its stake in shares of Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock valued at $40,000 after buying an additional 23 shares in the last quarter. Dunhill Financial LLC increased its holdings in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares in the last quarter. Simon Quick Advisors LLC raised its position in Vertex Pharmaceuticals by 1.1% in the 4th quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company’s stock worth $900,000 after purchasing an additional 24 shares during the last quarter. Spinnaker Trust lifted its holdings in Vertex Pharmaceuticals by 2.1% during the 4th quarter. Spinnaker Trust now owns 1,235 shares of the pharmaceutical company’s stock worth $497,000 after buying an additional 25 shares in the last quarter. Finally, Strategic Advisors LLC boosted its position in Vertex Pharmaceuticals by 0.6% in the 4th quarter. Strategic Advisors LLC now owns 4,486 shares of the pharmaceutical company’s stock valued at $1,807,000 after buying an additional 25 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 530 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the completion of the sale, the executive vice president now directly owns 58,539 shares of the company’s stock, valued at $27,825,928.26. This represents a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 1,084 shares of company stock valued at $505,512 in the last three months. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.